TL;DR — Retatrutide (development code LY3437943) is the first and, as of 2026, only known synthetic peptide to simultaneously activate all three incretin/glucagon-family receptors: GLP-1, GIP, and glucagon. Phase 2 clinical trial data (published in NEJM and related journals) have reported dose-dependent effects on body weight, glycaemic markers, and hepatic fat in human metabolic-disease populations — but Retatrutide remains investigational and is supplied strictly as a research compound. The B.A.B.E LABS catalogue carries Retatrutide via SHRED (10, 20, 30mg) and the SPRINGBREAK Bundle.
What is Retatrutide?
Retatrutide is a single-molecule synthetic peptide developed by Eli Lilly and given the development code LY3437943. It is engineered to bind and activate three receptors that are central to mammalian energy homeostasis:
1. GLP-1 receptor (glucagon-like peptide-1) — the target of semaglutide, liraglutide, and the first generation of incretin drugs
2. GIP receptor (glucose-dependent insulinotropic polypeptide) — co-targeted by tirzepatide alongside GLP-1
3. Glucagon receptor — the novel third axis. No approved drug before Retatrutide combined agonism at this receptor with GLP-1/GIP agonism
This triple-agonism is what distinguishes Retatrutide structurally and pharmacologically from all earlier incretin therapies.
The pharmacology: why three receptors matter
Mammalian energy balance is governed by an interconnected hormonal network. GLP-1 and GIP are incretins — released from the gut in response to nutrient intake and driving glucose-stimulated insulin release. Glucagon is the counter-regulatory hormone — released from pancreatic α-cells during fasting and driving hepatic glucose output and lipolysis.
Historically, pharmacology has targeted these receptors in isolation:
- Liraglutide / semaglutide — selective GLP-1 agonists
- Tirzepatide — dual GIP/GLP-1 agonist
- Retatrutide — triple GIP/GLP-1/glucagon agonist
The rationale for glucagon co-agonism is that glucagon receptor activation increases energy expenditure and lipolysis — complementing the appetite and insulin effects of GLP-1/GIP. Research has hypothesised that a balanced triple-agonist may produce greater composite effects on body weight and hepatic steatosis than any dual or single agonist.
What the clinical data has reported:
Phase 2 trials of Retatrutide (Jastreboff et al., NEJM 2023, and follow-ups) reported:
- Dose-dependent body weight reduction across 24- and 48-week dosing intervals
- Reductions in liver fat content measured by MRI-proton density fat fraction (MRI-PDFF) in populations with metabolic dysfunction-associated steatotic liver disease (MASLD)
- Glycaemic marker improvement (HbA1c, fasting glucose) in type 2 diabetes cohorts
- Dose-related gastrointestinal adverse effects consistent with the GLP-1/GIP class — nausea, vomiting, diarrhoea
Important: these are clinical trial findings in regulated patient populations. Retatrutide is supplied by B.A.B.E LABS only as a research compound for in-vitro and laboratory use. It is not TGA-approved and is not being supplied for human use.
Research context:
Retatrutide is an active subject of published and ongoing research. Topics that appear prominently in the literature include:
- Receptor selectivity ratios — the relative potency at each of the three receptors, and how this affects downstream signalling
- Ex-vivo and animal models of MASH, obesity, and type 2 diabetes
- Structural biology — the peptide engineering decisions that allow simultaneous agonism across three distantly related receptors
Purity and testing:
Every Retatrutide batch supplied by B.A.B.E LABS is:
- HPLC-tested ≥99% purity
- Mass-spec verified for expected molecular weight
- Accompanied by a Certificate of Analysis
Given Retatrutide's novelty and the volume of ongoing research, purity verification is particularly important — a contaminated research compound will confound downstream findings.
Dose sizes available:
SHRED is available in three vial strengths to accommodate different study protocols:
- 10 mg — smaller-scale in-vitro work
- 20 mg — mid-volume experimental series
- 30 mg — larger or longer-duration protocols
The Shred + Bronzed bundle:
SPRINGBREAK pairs Shred (Retatrutide) with Bronzed (Melanotan II). The two compounds engage entirely distinct receptor systems — incretin/glucagon vs melanocortin — so this is a bundle for researchers running parallel metabolic and melanocortin-pathway studies.
Storage:
- Lyophilised Retatrutide: –20°C, protected from light
- Reconstituted: 2–8°C, use within the window on the Certificate of Analysis
Research-use disclaimer:
Retatrutide is supplied strictly for in-vitro and laboratory research. It is not TGA-approved and is not for human consumption. Buyers must be 18+ and acknowledge they are conducting legitimate research.
FAQs
How is Retatrutide different from tirzepatide and semaglutide?
Semaglutide is a single GLP-1 agonist. Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide is a triple GLP-1/GIP/glucagon agonist — the glucagon receptor agonism is the structural novelty. In published clinical trials, the triple agonist has shown greater composite effects on body weight and hepatic fat than dual agonists, though head-to-head long-term data are still maturing.
Why does Retatrutide come in 10mg, 20mg, and 30mg sizes?
Different research protocols require different quantities. Buying a size that matches your study avoids mid-experiment re-reconstitution.
Is Retatrutide approved in Australia?
As of 2026, Retatrutide has not received TGA approval. It is available exclusively as a research compound and must not be used outside of in-vitro/laboratory research contexts.
What's the LY3437943 code?
It's Eli Lilly's internal development code. Many clinical trial publications cite this code rather than the generic name "Retatrutide".